Freemont Management S.A. Increases Position in Boston Scientific Corporation $BSX

Freemont Management S.A. boosted its position in Boston Scientific Corporation (NYSE:BSX) by 30.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,900 shares of the medical equipment provider’s stock after acquiring an additional 5,600 shares during the quarter. Freemont Management S.A.’s holdings in Boston Scientific were worth $2,567,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its position in Boston Scientific by 15.4% in the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after purchasing an additional 3,932 shares during the period. MRA Advisory Group bought a new position in shares of Boston Scientific during the second quarter valued at about $273,000. Bank of New Hampshire increased its holdings in shares of Boston Scientific by 552.0% in the second quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock worth $2,119,000 after buying an additional 16,699 shares during the period. NS Partners Ltd lifted its stake in shares of Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock valued at $37,143,000 after acquiring an additional 5,704 shares during the last quarter. Finally, New England Research & Management Inc. purchased a new stake in Boston Scientific during the 2nd quarter valued at about $1,133,000. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at $17,561,336.74. This trade represents a 21.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director owned 24,134 shares in the company, valued at $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 175,782 shares of company stock valued at $17,742,314 in the last three months. Corporate insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

BSX has been the topic of a number of analyst reports. Wells Fargo & Company lifted their price target on Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research note on Thursday, October 23rd. Morgan Stanley raised their target price on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a report on Wednesday, October 22nd. Jefferies Financial Group reissued a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Finally, Leerink Partners boosted their price objective on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $123.77.

Boston Scientific Trading Up 1.0%

NYSE:BSX opened at $100.05 on Friday. The company has a 50-day moving average price of $100.09 and a 200-day moving average price of $102.45. The stock has a market cap of $148.26 billion, a price-to-earnings ratio of 53.50, a P/E/G ratio of 2.02 and a beta of 0.58. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. Boston Scientific Corporation has a 12 month low of $85.98 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the prior year, the firm earned $0.63 earnings per share. Boston Scientific’s revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.